OBJECTIVES: Bleeding and thrombo-embolism are two of the most threatening adverse events associated with the use of continuous flow left ventricular assist devices (LVADs) in the treatment of severe heart failure. We analysed our LVAD patients treated with the HeartMate II (HM II) device by following a low anticoagulation regimen.
INTRODUCTION
The use of continuous flow (CF) left ventricular assist devices (LVADs) in the treatment of severe heart failure has become a widespread option to treat patients as a bridge to transplant (BTT) or for permanent long-term support-the so-called destination therapy (DT). The HeartMate II device (Thoratec Corporation, Pleasonton, CA, USA), an axial flow pump [1] , is the most common used LVAD worldwide, with more than 7000 implantations and more than 3000 patients on support. Several data and trials among the use of this LVAD system have proven not only a significantly better survival, but also an increase in health-related quality of life of LVAD patients [2, 3] . Due to the complex design of these rotary blood pumps, anticoagulation with phenprocumon or warfarin is mandatory, combined with an anti-platelet therapy. Thus, despite all improvements, this therapeutic option still carries the risk of severe adverse events, mainly bleeding and thrombo-embolism. During the last 2 years, the recommended anticoagulation suggests a less aggressive protocol than at the beginning of the use of CF LVADs [4, 5] . In the presented retrospective study, we reviewed our experience with the HM II LVAD in BTT and DT patients, following a mild anticoagulation protocol.
PATIENTS AND METHODS
In this retrospective, non-controlled study, we analysed the data sets of all 40 patients, who received an HM II LVAD from August 2008 till February 2011 in our institution. Fourteen of these patients were female (35%) and the mean body surface area (BSA) was 1.97 ± 0.22 m². The age ranged between 27 and 79 years with a mean of 58 ± 11.8 years, and 47.5% of them were >60 years. In 32 patients, the aetiology of cardiomyopathy (CM) was ischaemic (80%) and 5 were suffering from dilative cardiopathy. Additionally, two patients exhibited severe CM due to aortic valve disease and one young woman came down with postpartal CM. All patients were classified in New York Heart Association (NYHA) class IIIb or IV and were treated by maximum medical support including inotropic drugs or extracorporeal membrane oxygenation (ECMO). More than 52% (n = 21) were in INTERMACS levels 1 or 2. Instruments for further cardiac support were ECMO in 7 (17.5%), and intra-aortic balloon pump (IABP) in 15 cases (37.5%). The incidence of cardiopulmonary resuscitation within 1 week previously to the LVAD implantation was 22.5%.
The intention for this treatment was bridge to transplantation in 25 (62.5%), bridge to recovery in 1, bridge to candidacy in 5 (12.5%) and DT in 9 (22.5%) cases. All preoperative data are shown in Table 1 .
The implantation of the HM II LVAD was undertaken as a standard procedure by creating a pre-peritoneal pocket according to the company recommendation. After introducing cardiopulmonary bypass (CPB), the inflow cannula was implanted directly into the left ventricular apex. The pump was connected and the outflow graft was anastomosed to the ascending aorta. All procedures were carried out by a beating heart technique. In the last 22 cases, the operative field was filled by CO 2 for preventing air-embolism. The main intraoperative data are shown in Table 2 . After successful weaning from CPB, full protamin dose was given, and heparin was started only after 24 h postoperatively. The achieved partial thromboplastin time was 50 s. Phenprocumon (Phen) was given routinely after removal of the chest drains. Acetyl salicylic acid (ASA) was prescribed 50-100 mg/day only to patients <55 years or in case of severe atherosclerotic disease of the right coronary artery if there was a platelet count of >100 000 and no further blood loss through the chest drains. In our first 13 patients (2008-2009), the international normalized ratio (INR) target was 2.5. In the late period since 2010, it changed to 2.0-2.5 for all patients under HM II support.
We analysed patient data for all thrombo-embolic and bleeding events. Bleeding was defined as bleeding requiring surgical re-exploration (re-thoracotomy) or transfusion of >2 packed red cells within a 24-h period. All events were determined for two time periods: early postoperative events on postoperative days (PODs) 0-30, and late after PODs 30. Patient outcomes were determined as survival to transplantation, ongoing device support, left ventricular recovery or death on the device.
RESULTS

Clinical outcomes
All patients were followed consecutively up to the 30 April 2011. The duration of support ranged from 1 to 1052 days with a mean of 245 days and a total of 10 566 cumulative days on the device. The survival rate within 30 days was 87.5%. Of these five early deceased persons, four were classified in INTERMACS level 1 before LVAD implantation: three patients died of multiorgan failure (MOF), one of septic peritonitis and one of right heart failure (RHF). In the late period (>30 days), two other patients died during the initial hospitalization because of MOF and pneumonia.
Thirty-three patients could be discharged (82.5%) and 87% of these discharged patients were in NYHA class I or II after 3 months postoperatively. One male patient suffering from dilative cardiomyopathy was successfully weaned from LVAD after 9 months on support and 5 months later but still is classified in NYHA I. Only six patients were transplanted (15%). Three of the discharged patients died in the late period: one male patient committed suicide after 142 uneventful days on the device and two were re-admitted and died of multi-organ failure or rather RHF. Twenty-three patients are on the device in out-of-hospital care and are examined regularly every 6-8 weeks. No technical pump failures or fatal pump stops occurred. One HM II LVAD had to be exchanged due to driveline trauma. All patients, but two were put on phenprocumon, 16 of them with ASA (50-100 mg/day) and 2 of them with clopidogrel (75 mg/day). High-molecular-weight von-Willebrand factor multimers were measured in 26 patients and were reduced in all cases. Forty-two percent of the out-of-hospital patients were trained in the INR self-management successfully. Those patients who were completely taken off any anticoagulation were suffering from severe GI bleeding. Figure 1 shows the mean INR values from the LVAD implantation to the long-term follow-up of all the patients under phenprocumon. In this figure, the bars mark the mean INR values including the standard deviations.
In the early postoperative time period (<30 days), we could not find any thrombo-embolic event in our cohort. There was no ischaemic or haemorrhagic stroke. Surgical re-exploration because of severe bleeding was necessary in five patients (12.5%). One of these patients had to bear this re-thoracotomy twice. For three patients, we had to transfuse more than two packed red blood cells (PRBCs) within 24 h (7.5%). As described above, two patients suffered from severe life-threatening GI bleeding caused by widespread angiodyplasia in the entire gut. Therefore, they had to be removed completely from any anticoagulation, since there was absolutely no therapeutic option. Primarily, both patients underwent urgent LVAD implantation out of an INTERMACS level 1 and were not suspicious to have such a severe diagnosis before the procedure. Meanwhile, both are well without any signs of thrombo-embolic or bleeding events after 12 months and 6 months, respectively, on the device. Beside the reduced high-molecular-weight von-Willebrand factor multimers, these two patients had a considerably reduced platelet function without any platelet inhibitor treatment [ platelet function analyser (PFA) testing, see Table 3 ].
During the late time period, two patients developed thromboembolic events (5%). Both patients were not trained in the INR self-management. The first patient was a 64 year old woman with a DT intention and an ischaemic cardiac disease. She was under phenprocumon and ASA, but showed a poor clinical compliance. She was admitted to an outer hospital with signs of paraplegia. The INR was 1.35 at the index event and the CT scan exhibited an ischaemic media-stroke of the left hemisphere. She recovered well from the paraplegia and was discharged after 7 days. In the second patient-a 50 year old male patient from the BTT group-an ischaemic stroke was found by chance during a routine check-up. Because of some decent disturbances in his sight, a CT scan was established, revealing an occipital ischaemia. Also, this patient exhibited an INR below 1.4 and had stopped the ASA self-dependently because of gastric pain some weeks previously. He recovered well, but still is suffering from visus problems. After another 4-month period, he developed an LVAD pump thrombosis during a weaning protocol and the system was 
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A.K. Menon et al. / European Journal of Cardio-Thoracic Surgeryexplanted successfully. This was the only LVAD pump thrombosis in our group of patients (2.5%). There were no further thromboembolic events in our patient group. During the late time period, only three bleeding events appeared in three patients. One female patient was readmitted because of GI bleeding (Phen + ASA) with an INR value of >3.5 at the index event. She was evaluated directly and transplanted on day 53 after the LVAD implantation. Another male patient had to be re-transfused without any bleeding source in the endoscopic examination. Unfortunately, this patient suffered from several severe diagnosis such as chronic obstructive pulmonary disease (COPD), renal insufficiency, polyneuropathy and impaired liver function and died because of MOF 254 days after LVAD implantation. The third case was a DT patient with an uncontrolled INR of >5, who was re-admitted because of an intra-pericardial bleeding and had to undergo urgent re-sternotomy 14 days after discharge. This patient died of RHF 45 days postoperatively. There were no haemorrhagic strokes in the late postoperative period.
All adverse thrombo-embolic or bleeding events are shown in Table 4 . The incidence for bleeding events in the long-term follow-up was 7.5%.
DISCUSSION
During the past years, the use of CF LVADs has led to an enormous change in the possibilities of the enduring treatment of end-stage heart failure. Compared with the older, bulky pulsatile LVAD pumps, they are able to obtain a better survival, improvement of functional capacity and quality of life in the younger BTT group, as well as in the DT patient group [2, 3] . Even in patients with an impaired right ventricular function, LVAD implantation is more feasible because of the combination with transient right ventricular support strategies [6, 7] . Despite all ameliorations, this therapeutic option still carries the risk of severe adverse events, mainly bleeding and thrombo-embolism. Especially, the nonsurgical bleeding episodes such as gastrointestinal bleeding in association with the occurrence of an acquired von-Willebrand syndrome (AVW) is discussed vividly [8, 9] .
However, still the main risk early postoperatively is bleeding with an incidence from up to 50% in the US and European studies [1] [2] [3] [4] 10] . Mainly, the transfusion of PRBCs has the highest incidence between 18 and 50% [4, 10] . Compared with these findings, our early transfusion rate of 7.5% is remarkably low, calculated by >2 PRBCs per 24 h.
Maybe, this is due to the fact that we do not apply for any anticoagulation medication within the first 24 h postoperatively and we were looking closely after the count of thrombocytes, before we start any additional anti-platelet therapy.
The second main threat of the early period postoperatively is bleeding requiring surgical re-exploration. The incidence in the literature varies from 10 to 30% [1] [2] [3] [4] 10] . Again, according to the findings mentioned above, our data exhibit an ordinary acceptable re-sternotomy rate of 12.5%.
Despite this already mentioned moderate anticoagulation protocol in the early postoperative period, we had no thromboembolic event in our HM II LVAD patient group. Giving consideration to the other studies, these are absolutely comparable results.
Encouraged by the newer findings of Boyle et al. [5] , we reduced the regimen for our out-of-hospital patients according to their individual risk profile, e.g. our INR target was modified to 2.0. Figure 1 shows clearly that our patients under phenprocumon are well managed without relevant meanderings from aimed INR target of 2.0.
Additionally, the new awareness that apparently every patient on a CF LVAD is developing an AVW syndrome [8] was correlated to the higher incidence of gastrointestinal bleedings in the longterm support [11] . In this outstanding contribution, Uriel et al. [11] impressively demonstrated the high risk for each patient on a CF LVAD to bleed over the time even if this patient remains within the low borders of the recommended target INR range from the Boyle group. Despite the INR was averaged 1.67 and the platelet counts were within the normal range, >44% of these patients developed bleeding events, mostly GI bleeding. This opens further considerations concerning the complexity of interaction in anticoagulation under the use of a CF LVAD. Secondly, Uriel shows very clearly that the bleeding risk rises with the patient age: the risk of bleeding for a patient >66 years is supposed to be 65%. Therefore, we tried to prevent ASA medication in the older patient group and restricted the anti-platelet therapy on the patients who are <55 years or in patients suffering from severe sclerosis of the right coronary artery to prevent from a potential RHF caused by myocardial infarction. This resulted in a remarkably low bleeding rate in the long term: re-transfusion was only necessary in 2.5%, and there was only one surgical re-exploration. Again, there was no haemorrhagic stroke in our cohort over the long-term period. The incidence for gastrointestinal bleeding was below 3% over the time. Respecting the literature, the re-transfusion rate is mentioned to be about 19-30%.
However, we tested the high-molecular-weight von-Willebrand factor multimers and found a typical reduction in 100% of our LVAD patients, independently from the anticoagulation regimen. Even the two patients without any anticoagulation exhibited these findings.
The two patients of our cohort, who developed thrombotic events, were exactly out of the borderline Boyle et al. defined in their publication in 2009. Whether the self-depending stop of the prescribed ASA in the second patient would have avoided the device thrombosis is questionable. Nevertheless, in this case, the reduced pump speed, due to the established weaning protocol, surely contributed to the higher risk of developing a thrombosis anyway.
In conclusion, compared with the other study results, our data suggest that a notably mild anticoagulation protocol does not increase the risk of severe thrombo-embolic events in the early and late postoperative period after the implantation of the HM II CW LVAD. Furthermore, this mild regime is helpful in reducing the still unacceptably high incidence of bleeding episodes in the use in this patient group.
